SynthesisScientific reports2025
Risk factors for invasive fungal infections in adult patients with hematological malignancies and/or stem cell transplant: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Dematiaceous Fungal Infections in Hematopoietic Stem Cell Transplantation and Predisposing Hematological Conditions: A Systematic Review.Journal of fungi (Basel, Switzerland) · 2026Review
- First report ofMedical mycology case reports · 2026Article
- Fungal Infections Associated with Sphingosine 1-Phosphate Receptor Modulators: Immunological Mechanisms, Clinical Patterns, and Management Considerations.Microorganisms · 2026Review
- Cutaneous Invasive Opportunistic Fungal Infections in Dogs Receiving Ciclosporin for Immune-Mediated Diseases: A Case-Control Study.Veterinary dermatology · 2026Article
- Dynamics of 1,3-β-D-Glucan in Invasive Candidiasis: A Narrative Review of Microbiological Aspects and Diagnostic Implications.Antibodies (Basel, Switzerland) · 2026Review
- Candida Esophagitis in Patients with Solid Organ Cancers.Journal of clinical medicine · 2026Review
- Presentation, management, and outcomes of orbital infections in patients with cancer.Frontiers in ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improving prevention and treatment strategies for invasive fungal infections (IFI) is essential to reduce associated morbidity and mortality. We performed a systematic review and meta-analyses to assess factors associated with IFI in adult patients with hematological malignancies and/or hematopoietic stem cell transplantation (HSCT). DATA SOURCES: We searched PubMed, Embase, CENTRAL and the grey literature from 01/01/2002 to 08/02/2024. STUDY ELIGIBILITY CRITERIA: Eligible studies were case-control or cohort studies including adult patients with hematological malignancies and/or HSCT and reporting risk factors for IFI.
participantsAdult patients with hematological malignancies and/or HSCT. Assessment of risk of bias. Risk of bias assessment was assessed independently using the Critical Appraisal Skills Programme checklists for cohort studies and case-control studies. Methods of data synthesis. Study selection and data extraction were done independently. Adjusted estimates were pooled using random effects models. Among 12 624 references identified, 69 studies (reporting 2917 IFI) were included in the systematic review, 20 of which were included in meta-analyses. Factors independently associated with IFI included previous allo-HSCT (pooled aHR 3.21 [95%CI 1.54-6.71]), especially with a haploidentical donor (pooled aHR 2.41 [95%CI 1.27-4.57]), acute graft vs. host disease (aGvHD) ≥ 2 (pooled aHR 2.59 [95%CI 1.36-4.90]), corticosteroids (pooled aOR 2.84 [95%CI 1.42-5.70]) or T-cell depleting agents (pooled aOR 2.73 [95%CI 1.61-4.64]). Antifungal prophylaxis was a protective factor for IFI (pooled aOR 0.20 [95%CI 0.13-0.28]). The identification of factors independently associated with IFI may help to stratify IFI risk among hematological patients. REGISTRATION: PROSPERO, CRD42023429103.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.